Reasons for lack of referral to medical oncology for systemic therapy in stage IV non-small-cell lung cancer: comparison of 2003-2006 with 2010-2011.

Ko, J J; Tudor, R; Li, H; Liu, M; Skolnik, K; Boland, W Kells; Macklow, J; Morris, D; Bebb, D G

Ko, J J; Tudor, R; Li, H; Liu, M; Skolnik, K; Boland, W Kells; Macklow, J; Morris, D; Bebb, D G.

Afiliación

Ko JJ; Department of Systemic Therapy, Abbotsford Cancer Centre, BC Cancer Agency, University of British Columbia, Vancouver, BC.
Tudor R; Department of Medical Oncology, Tom Baker Cancer Centre.
Li H; Department of Oncology and Community Health Sciences, University of Calgary.
Liu M; Analytics (Data Integration, Measurement and Reporting), Alberta Health Services, and.
Skolnik K; Faculty of Medicine, University of Calgary, Calgary, AB; and.
Boland WK; Faculty of Medicine, Weill Cornell Medical College, New York, NY, U.S.A.
Macklow J; Department of Medical Oncology, Tom Baker Cancer Centre.
Morris D; Department of Medical Oncology, Tom Baker Cancer Centre.
Bebb DG; Department of Medical Oncology, Tom Baker Cancer Centre.

Curr Oncol ; 24(6): e486-e493, 2017 Dec.

Article en En | MEDLINE | ID: mdl-29270057

Palabras clave

Non-small-cell lung cancer; chemotherapy; immunotherapy; reasons for no treatment; referral patterns; stage iv; survival; targeted therapy

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Curr Oncol Año: 2017 Tipo del documento: Article